Dominik Baron

AIMS: The DanGer Shock (DGS) trial demonstrated that the routine use of a microaxial flow pump (mAFP) with standard care to treat STEMI-related cardiogenic shock (STEMI-CS) led to a lower risk of all-cause death at 180 days than standard care alone. We investigated the impact of patient eligibility for DGS in an all-comers cardiogenic shock registry of patients receiving a mAFP.

Introduction Cardiogenic shock (CS) is an acute haemodynamic compromise of cardiac origin characterized by low cardiac output and consequent tissue malperfusion.1 It can be caused by multiple diseases, present in a spectrum of severity from beginning to extremis CS according to the Society for Cardiovascular Angiography and Interventions (SCAI) SHOCK classification system, and can be divided into predominant left, right or biventricular failure.1, 2 Besides heart failure related CS, acute...